The Pharma Data

APRIL 14, 2021

Bamlanivimab and etesevimab together and bamlanivimab alone are not authorized for use in patients: who are hospitalized due to COVID-19, OR. Treatment with bamlanivimab and etesevimab together has not been studied in patients hospitalized due to COVID-19. Some of these events required hospitalization. Adverse Events.

Government 52

Government Hospitals Long-Term Care Facilities Treatment 52

The Pharma Data

SEPTEMBER 18, 2020

Olivia Karpinski, vice-president of sales at Vivera Pharmaceuticals, said: “We have worked closely with our customers, including long-term care facilities and hospital networks, to provide efficient solutions for their increased testing needs.”

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

DECEMBER 10, 2020

First in line are health care personnel and residents and staff of long-term care facilities, according to earlier recommendations released by the CDC panel. Third of Americans live where hospitals short on ICU beds. The new hospital data shows that some areas — like Amarillo, Texas; Coral Gables, Fla.;

Vaccine 52

Vaccine FDA Long-Term Care Facilities Hospitals 52

The Pharma Data

OCTOBER 28, 2020

is experiencing a surge in COVID-19 cases and associated hospitalizations, and we believe bamlanivimab could be an important therapeutic option that can bring value to the overall healthcare system, as it has shown a potential benefit in clinical outcomes with a reduction in viral load and rates of symptoms and hospitalizations.”

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

DECEMBER 2, 2020

The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. Hospitalizations reach record high.

Vaccine 40

Vaccine Long-Term Care Facilities Hospitals Nurses 40

The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Patients treated with bamlanivimab showed reduced viral load and rates of symptoms and hospitalization.

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

APRIL 16, 2021

More than 400,000 patients have been treated with bamlanivimab – more than any other neutralizing antibody – potentially preventing more than 20,000 hospitalizations and at least 10,000 deaths during the worst of the pandemic in the U.S. Some of these events required hospitalization. Limitations of Authorized Use. Adverse Events.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

JANUARY 26, 2021

“The death toll from COVID-19 continues to rise around the world and hospitalizations, particularly in the U.S., These data further support our belief that bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and death in high-risk COVID-19 patients.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

MARCH 11, 2021

These results are consistent with those seen in other data sets from BLAZE-1: in the previous Phase 3 cohort, bamlanivimab 2800 mg with etesevimab 2800 mg reduced the risk of hospitalizations and deaths by 70 percent and in the Phase 2 cohort, bamlanivimab alone reduced the risk of hospitalizations and ER visits by approximately 70 percent.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40

The Pharma Data

MARCH 5, 2021

Results from BLAZE-1 demonstrated bamlanivimab alone reduced viral load and symptoms and also reduced COVID-19 hospitalizations by approximately 70 percent, and bamlanivimab and etesevimab together reduced the risk of COVID-19 hospitalizations and death by 70 percent in non-hospitalized high-risk patients with mild to moderate COVID-19.

Treatment 40

Treatment Hospitals Long-Term Care Facilities Therapies 40

The Pharma Data

MAY 4, 2021

Direct Relief will allocate donations of baricitinib to low- and lower-middle-income countries (based on World Bank classification) for the treatment of hospitalized COVID-19 patients requiring supplemental oxygen, based on requests from these governments to Direct Relief. It is approved in the U.S. See the full Prescribing Information here.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

JANUARY 24, 2021

Innovation Pharmaceuticals received the greenlight from the FDA to initiate a Phase II trial of Brilacidin in hospitalized COVID-19 patients. It was run at nine hospitals in Brazil from May 8 to July 17, 2020. The drug appears to inhibit IL-6, IL-1beta, TNF-alpha and other pro-inflammatory cytokines and chemokines.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

Another record-breaking day of COVID-19 hospitalizations and deaths underscored Redfield’s grim warning. The number of people hospitalized for COVID-19 on Wednesday passed 100,000, nearly double the highest point seen last spring. With hospitals filling up in multiple states, the days ahead do appear bleak.

Hospitals 52

Hospitals Vaccine Long-Term Care Facilities Nurses 52

The Pharma Data

SEPTEMBER 6, 2021

To complement vaccination efforts, it is also crucial to continue applying measures such as physical distancing, hand and respiratory hygiene, and using face masks where needed, in particular in high-risk settings such as long-term care facilities or hospital wards with patients at risk of severe COVID-19.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Immune Response Virus 52

The Pharma Data

DECEMBER 4, 2020

That response is facing its toughest challenge so far, as daily case counts, hospitalizations and deaths continue to set records on a daily basis. “If we don’t act now our hospital system will be overwhelmed,” Gov. Gavin Newsom said. “If we don’t act now, we’ll continue to see our death rate climb.”

Vaccine 52

Vaccine Long-Term Care Facilities Nurses Hospitals 52

The Pharma Data

JANUARY 8, 2021

But, hopefully, as part of such a plan there will be assurance that more vaccine doses will be produced to ensure patients get their second dose,” said Dr. David Hirschwerk, attending physician in infectious diseases at North Shore University Hospital, in Manhasset, N.Y.

Vaccine 52

Vaccine Long-Term Care Facilities Hospitals FDA 52

The Pharma Data

DECEMBER 31, 2020

According to the Times , he said that health care facilities are still learning how to store the vaccines at super-low temperatures, and many states are setting aside doses for use at long-term care facilities, an effort that’s expected to take several months.

Vaccine 52

Vaccine Long-Term Care Facilities Virus Hospitals 52